Indaptus Therapeutics, Inc. INDP

Company Overview

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies designed to activate the innate immune system for the treatment of cancer and infectious diseases. The company operates within the biotechnology and immuno-oncology sectors, with research centered on systemic anti-tumor immune activation using proprietary bacterial-derived therapies. Its primary product platform is based on “Killed but Metabolically Active” (KBMA) technology, which uses engineered and attenuated Gram-negative bacteria intended to stimulate multiple innate immune pathways simultaneously.

The company’s lead product candidate, Decoy20, is being evaluated as an intravenous immunotherapy designed to trigger broad immune responses through activation of toll-like receptors and other immune signaling mechanisms. Indaptus primarily targets oncology indications, including solid tumors that may be resistant to checkpoint inhibitors or other immunotherapies. The company was founded in 2010 and later became publicly traded on the Nasdaq Capital Market under the ticker INDP. Its strategic positioning is based on combining broad innate immune activation with potentially lower toxicity than live bacterial therapies, differentiating it from traditional cytokine-based or single-target immunotherapy approaches.